AU2004271978B2 - Ophthalmic compositions for treating ocular hypertension - Google Patents

Ophthalmic compositions for treating ocular hypertension Download PDF

Info

Publication number
AU2004271978B2
AU2004271978B2 AU2004271978A AU2004271978A AU2004271978B2 AU 2004271978 B2 AU2004271978 B2 AU 2004271978B2 AU 2004271978 A AU2004271978 A AU 2004271978A AU 2004271978 A AU2004271978 A AU 2004271978A AU 2004271978 B2 AU2004271978 B2 AU 2004271978B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
heterocyclyl
aryl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004271978A
Other languages
English (en)
Other versions
AU2004271978A1 (en
Inventor
Meng Hsin Chen
James B. Doherty
Luping Liu
Swaminathan Natarajan
Robert M. Tynebor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2004271978A1 publication Critical patent/AU2004271978A1/en
Application granted granted Critical
Publication of AU2004271978B2 publication Critical patent/AU2004271978B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
AU2004271978A 2003-09-04 2004-08-31 Ophthalmic compositions for treating ocular hypertension Ceased AU2004271978B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50009003P 2003-09-04 2003-09-04
US60/500,090 2003-09-04
PCT/US2004/028351 WO2005025568A1 (en) 2003-09-04 2004-08-31 Ophthalmic compositions for treating ocular hypertension

Publications (2)

Publication Number Publication Date
AU2004271978A1 AU2004271978A1 (en) 2005-03-24
AU2004271978B2 true AU2004271978B2 (en) 2009-02-05

Family

ID=34312180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004271978A Ceased AU2004271978B2 (en) 2003-09-04 2004-08-31 Ophthalmic compositions for treating ocular hypertension

Country Status (7)

Country Link
US (1) US7494983B2 (US07494983-20090224-C00018.png)
EP (1) EP1663221A4 (US07494983-20090224-C00018.png)
JP (1) JP2007504236A (US07494983-20090224-C00018.png)
CN (1) CN1842335A (US07494983-20090224-C00018.png)
AU (1) AU2004271978B2 (US07494983-20090224-C00018.png)
CA (1) CA2537430A1 (US07494983-20090224-C00018.png)
WO (1) WO2005025568A1 (US07494983-20090224-C00018.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1663987B1 (en) * 2003-09-04 2009-03-18 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531491B1 (en) * 1999-07-02 2003-03-11 Agouron Pharamaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ATE101342T1 (de) 1988-09-06 1994-02-15 Kabi Pharmacia Ab Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
JPH08511024A (ja) 1993-06-08 1996-11-19 バイディ ファーマシューティカルズ 眼内圧を低下させる方法および組成物
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU1293101A (en) 1999-12-22 2001-07-03 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
AU1918001A (en) * 2000-03-17 2001-10-03 Alcon Universal Ltd 5-hydroxy indazole derivatives for treating glaucoma
EP1268438A1 (en) 2000-03-17 2003-01-02 Alcon, Inc 6-hydroxy-indazole derivatives for treating glaucoma
EP1186287A1 (en) 2000-03-31 2002-03-13 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
CA2429850C (en) 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
BR0210241A (pt) * 2001-06-01 2004-08-10 Alcon Inc Piranoindazóis e seu uso no tratamento de glaucoma
US7528163B2 (en) * 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531491B1 (en) * 1999-07-02 2003-03-11 Agouron Pharamaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Also Published As

Publication number Publication date
AU2004271978A1 (en) 2005-03-24
EP1663221A4 (en) 2009-04-22
US20070027188A1 (en) 2007-02-01
CN1842335A (zh) 2006-10-04
US7494983B2 (en) 2009-02-24
JP2007504236A (ja) 2007-03-01
CA2537430A1 (en) 2005-03-24
WO2005025568A1 (en) 2005-03-24
EP1663221A1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
JP5061293B2 (ja) 高眼圧治療用眼科組成物
CA2583622A1 (en) Ophthalmic compositions for treating ocular hypertension
AU2003287481B2 (en) Ophthalmic compositions for treating ocular hypertension
AU2005274972A1 (en) Ophthalmic compositions for treating ocular hypertension
EP1515721A1 (en) Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en) Ophthalmic compositions for treating ocular hypertension
US20060154897A1 (en) Ophthalmic compositions for treating ocular hypertension
ZA200503134B (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired